On the public citation graph

Clinical pharmacology as a cornerstone of orphan drug development

0 signed · 30 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/pst.394openalex-snapshot
Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study
inferredcites →https://doi.org/10.1038/clpt.2010.298openalex-snapshot
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
inferredcites →https://doi.org/10.1038/nrd3160openalex-snapshot
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years
inferredcites →https://doi.org/10.1038/nrd3275openalex-snapshot
Rare diseases, orphan drugs and their regulation: questions and misconceptions
inferredcites →https://doi.org/10.1038/sj.clpt.6100051openalex-snapshot
Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1002/9781118312087.ch13openalex-snapshot
Rare Diseases and Orphan Drugs
inferred← citeshttps://doi.org/10.1002/cpt.417openalex-snapshot
Making Every Subject Count: A Case Study of Drug Development Path for Medication in a Pediatric Rare Disease
inferred← citeshttps://doi.org/10.1002/jcb.25799openalex-snapshot
An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer
inferred← citeshttps://doi.org/10.1002/jcph.2173openalex-snapshot
Think Rare, Think Inside and Out: Simple Question‐Based Approach to Complex Rare Disease Drug Development
inferred← citeshttps://doi.org/10.1002/jcph.599openalex-snapshot
A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
inferred← citeshttps://doi.org/10.1002/jps.23570openalex-snapshot
The Utility of Modeling and Simulation in Drug Development and Regulatory Review
inferred← citeshttps://doi.org/10.1007/s00018-020-03727-0openalex-snapshot
Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige
inferred← citeshttps://doi.org/10.1007/s10529-015-1908-zopenalex-snapshot
Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story
inferred← citeshttps://doi.org/10.1007/s40262-017-0616-3openalex-snapshot
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
inferred← citeshttps://doi.org/10.1016/b978-0-12-385471-1.00036-2openalex-snapshot
The Role of the FDA in Guiding Drug Development
inferred← citeshttps://doi.org/10.1016/j.drudis.2013.06.012openalex-snapshot
EU marketing authorization review of orphan and non-orphan drugs does not differ
inferred← citeshttps://doi.org/10.1038/clpt.2011.320openalex-snapshot
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
inferred← citeshttps://doi.org/10.1038/clpt.2011.352openalex-snapshot
Regulatory Science and the Role of the Regulator in Biomedical Innovation
inferred← citeshttps://doi.org/10.1038/clpt.2012.23openalex-snapshot
Clinical Pharmacology and Orphan Drugs: An Informational Inventory 2006–2010
inferred← citeshttps://doi.org/10.1038/clpt.2012.37openalex-snapshot
The Many Sides of Off-Label Prescribing
inferred← citeshttps://doi.org/10.1038/clpt.2012.80openalex-snapshot
Quantitative Analysis to Guide Orphan Drug Development
inferred← citeshttps://doi.org/10.1038/clpt.2012.83openalex-snapshot
The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases
inferred← citeshttps://doi.org/10.1038/clpt.2012.97openalex-snapshot
Rare Diseases: The Bane of Modern Society and the Quest for Cures
inferred← citeshttps://doi.org/10.1038/clpt.2013.32openalex-snapshot
Clinical Pharmacology and the Catalysis of Regulatory Science: Opportunities for the Advancement of Drug Development and Evaluation
inferred← citeshttps://doi.org/10.1111/bcp.15090openalex-snapshot
Translational and clinical pharmacology considerations in drug repurposing for X‐linked adrenoleukodystrophy—A rare peroxisomal disorder
inferred← citeshttps://doi.org/10.1111/cts.13362openalex-snapshot
Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non‐orphan drugs approved by the FDA
inferred← citeshttps://doi.org/10.1111/fcp.12314openalex-snapshot
Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology
inferred← citeshttps://doi.org/10.1124/pr.111.005769openalex-snapshot
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
inferred← citeshttps://doi.org/10.1590/s1676-26492011000400006openalex-snapshot
Droga órfã: surgimento de um novo conceito
inferred← citeshttps://doi.org/10.4155/fmc.14.65openalex-snapshot
The Discovery of Medicines for Rare Diseases
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.